Last reviewed · How we verify
Clevudine, Adefovir
Clevudine and Adefovir, marketed by Bukwang Pharmaceutical, are antiviral drugs with a key composition patent expiring in 2028. The primary strength of these drugs lies in their established market presence and ongoing revenue generation. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | Clevudine, Adefovir |
|---|---|
| Sponsor | Bukwang Pharmaceutical |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study With Clevudine Monotherapy or Adefovir and Clevudine Combination in Proportion to Roadmap Concept in Patients With HBV Associated-HCC (PHASE4)
- A Pilot Study to Evaluate the Safety and Efficacy of Clevudine or Adefovir Patients With LC-B (PHASE3)
- An Open Study to Evaluate the Efficacy, Safety of Clevudine Monotherapy or Adefovir and Clevudine Combination in Patients With Chronic Hepatitis B (PHASE4)
- A Study With Clevudine Monotherapy or Adefovir and Clevudine Combination in Patients With Chronic Hepatitis B (PHASE4)
- An Study of Efficacy and Safety of Clevudine (PHASE3)
- A Clinical Trial to Investigate the Pharmacokinetic Drug-drug Interaction of Clevudine and Adefovir Dipivoxil After Oral Administration in Healthy Male Subjects (PHASE1)
- Switch From Adefovir to Tenofovir in Chronic Hepatitis B for Suboptimal Response to Adefovir-based Combination Therapy (PHASE4)
- A Double-Blind Randomized Clinical Trial Comparing the Safety and Antiviral Activity of 48-week Clevudine and Adefovir Dipivoxil in HBeAg(-) Chronic Hepatitis B With Compensated Liver Function (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Clevudine, Adefovir CI brief — competitive landscape report
- Clevudine, Adefovir updates RSS · CI watch RSS
- Bukwang Pharmaceutical portfolio CI